74 results about "Androgen dependent" patented technology

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

Androgens and their derivates and analogs, such as anabolic agents, are characterized by at least one substituent or substituent grouping with radical trapping properties. These compounds are used as androgen or anabolic agent substitutes or therapeutical agents for treating androgen defficiency; for treating benign prostate hypertrophy and prostate carcinome, in particular with a testosterone-based compound; for treating osteoporosis, in particular post-menopausal osteoporosis in women, preferably associated with estrogen and / or gestagens; for treating brain oedema induced by vasculary or ischemic troubles, subarachnoidal bleeding, ischemic shock and cerebral insult; for treating asthma in its various forms, for treating Alzheimer's disease, Parkinson's disease; for organ transplants; and for treating androgen-dependent and non androgen-dependent malign neoplasia

Compounds having the structure or their salts: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Some of these compounds having tissue-specific antiandrogenic activity and tissue-specific androgenic activity can be used to treat or reduce the risk of developing diseases related to loss of androgenic stimulation. Combinations with other active pharmaceutical agents are also disclosed.

The invention concerns cDNA molecules encoding HRPCa 9 and HRPCa 10 both of which are constitutively expressed in the androgen-independent cell line, LN3 LNAcP and induced by testosterone in the androgen-dependent cell line, LNAcP.The invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention. The invention also provides screening assays which can be used to identify compounds useful for the treatment of prostate cancer (e.g., androgen-independent prostate cancer).

Compounds having the structure, their salts or N-oxide derivatives:are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.

Bimatoprost, a prostamide F2 alpha analog, used alone or in combination with other prostamides, or prostaglandin analogs, in a topical manner for the promotion of hair growth in mustache, beard, chest and other androgen dependent hair growth areas in humans and animals.

The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells invariably become androgen independent (AI) and tumor growth follows. The invention inhibits or delays transition of androgen dependent cancer to androgen independent cancer, significantly decreases risk of recurrence, and improves treatment outcome.

The invention provides an immunogenic composition comprising a GnRH multimer and an antigenic carrier, an immunogenic composition comprising a recombinant vector containing a nucleic acid molecule encoding a GnRH multimer and optionally an antigenic carrier, antibodies elicited by the immunogenic compositions, and methods of using the immunogenic compositions and antibodies for modifying sexual physiology and behavior, improving the organoleptic properties of meat, and treating androgen-dependent prostate tumors and GnRH-sensitive ovarian tumors.

The present invention provides synthetic ribozyme oligonucleotides alone and within constructs. The ribozyme gene provides methods for the treatment of prostate hyperplasia and other androgen dependent pathologies. Improved therapies for such diseases are provided without significant hormonal imbalance and without surgical intervention. Also provided are techniques for selecting and synthesizing effective and specifically targeted molecular tools for use in inhibiting androgen receptor gene expression.

A treatment for cancer using a combination therapy including an inhibitor of the PI3K / Akt pathway in combination with roscovitine. It is shown that the combination of roscovitine and API-2 (Triciribine) or roscovitine and LY294002 induce the apoptosis of androgen-dependent (LNCaP) and androgen-independent (PC3) prostate cancer cells. Two important results have been observed. First, cells that respond to roscovitine alone (LNCaP) initiate apoptosis sooner when co-treated. Second, cells that do not respond to roscovitine alone (PC3) apoptose when co-treated, although with delayed kinetics. In the absence of roscovitine, AKT inhibitors had no effect on LNCaP or PC3 survival, and in both cell lines, the combined treatment activated the mitochondrial pathway of apoptosis. Importantly, normal epithelial cells (RPWE) remained viable in the presence of roscovitine and AKT inhibitors. Events elicited by roscovitine (down-regulation of XIAP) and AKT inhibitors (accumulation of Bim) in LNCaP and PC3 cells are identified. Additional data show that PC3 cells apoptose when treated with AKT inhibitors and depleted of either XIAP or Cdk9. Taken together, these important results lead to improved treatments for cancers, such as prostate cancer, through the combination therapies taught herein.

Disclosed herein are compositions for controlling androgen activity in target organs and cells through the modulation of a 5-α-reductase activity. In certain aspects, these compositions are employed to modulate androgenic activity by inhibiting the formation and availability of active androgen in target cells. As a result, the present invention is directed toward the treatment of a wide variety of conditions including, but not limited to, the treatment of prostatic hyperplasia, prostatic cancer, hirsutism, acne, male pattern baldness, seborrhea, and other diseases related to androgen hyperactivity. Several of these compositions have been shown to effectively decrease body weight, and in some cases, to decrease the weight of an androgen-dependent body organ, such as the prostate and other organs.

Androgen nucleus derivatives having specified substituents at the 17 alpha position are disclosed for use as antiandrogens for the treatment of androgen-dependent diseases. In some preferred embodiments, the compound is formulated together with pharmaceutically acceptable diluent or carrier for topical use in the treatment of androgen-dependent diseases associated with the skin.

Biphenyl derivatives are disclosed for use in the treatment of androgen-dependent diseases such as prostate cancer, benign prostatic hyperplasia, precicious puberty, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and premature male baldness. For example, some preferred compounds having the structure: are formulated together with pharmaceutically acceptable diluent or carrier for topical use in the treatment of androgen-dependent prostate cancer.

Chimeric polypeptides comprising a dihydrotestosterone (DHT) reductase moiety, such as 3 alpha-hydroxysteroid dehydrogenase (3α-HSD), fused to a signal peptide moiety, polynucleotides encoding same, and compositions comprising at least one microorganism cell capable of secreting the chimeric polypeptide, are provided. Further provided are methods and kits for treating, preventing or ameliorating androgen-dependent disorders, including but not limited to androgenic alopecia.

This invention provides a novel class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds which are tissue-selective androgen receptor modulators (SARM), which are useful for oral testosterone replacement therapy, male contraception, maintaining sexual desire in women, treating prostate cancer and imaging prostate cancer. These agents have an unexpected in-vivo activity for an androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. These agents may be active alone or in combination with progestins or estrogens. The invention further provides a novel class of nonsteroidal agonist compounds and methods of binding an androgen receptor, modulating spermatogenesis, treating and imaging prostate cancer, and providing hormonal therapy for androgen-dependent conditions.

Disclosed herein are methods of inhibiting or delaying the growth of androgen-dependent prostate cancer, and / or inhibiting or delaying the onset of castration-resistant prostate cancer (CRPC) by administering naphthoquinone analogs, such as plumbagin, and specified hormone therapy agents, including selective inhibitors of 17,20-lyase activity of CYP 17.

The invention provides a transgenic mouse and cell lines with a homozygous disruption of a chromosomal PTEN gene in prostate cells. The mouse progresses from hyperplasia to metastatic cancer and can be used to identify prostate cancer therapeutics and genes that are differentially regulated during androgen dependent and androgen independent prostate cancer progression.

The invention provides an inhibitor for CYP11B, CYP17 and / or CYP21 as shown in a formula A. The inhibitor is used for treating androgen dependent diseases and symptoms.

Novel chemopreventive and chemotherapeutic cancer treatment method using elemental selenium nanoparticles. Cancer cells, especially androgen dependent prostate cancers are exposed to selenium from elemental selenium nanoparticle treatment, and apoptosis is induced in the cancer cells.

Disclosed herein are methods and compositions for the treatment of prostate cancer with an IGF-1 receptor kinase inhibitor. Methods are also provided for the treatment of prostate cancer by identifying a level of IGF-1 receptor expression and making a decision whether to treat with an IGF-1 receptor kinase inhibitor.

There are disclosed compounds of the formula (I): prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17β-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases.

Compounds having the structure or their salts:are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia, male baldness, muscle atrophy and weakness, sarcopenia, male hypogonadism, erectile dysfunction, female sexual dysfunction and osteoporosis. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.

The present invention provides a mutant androgen receptor (AR) useful for screening an agent for the prophylaxis / treatment of androgen-independent cancer and the like, DNA encoding the AR and the like. It also provides a method of producing a mutant AR expressing cancer cell line in vitro, a method of screening for an anti-antiandrogen drug using the mutant AR expressing cancer cell line obtained by this method, a method of classifying anti-androgen drugs, a cocktail therapy agent comprising a combination of anti-androgen drugs classified by this method and the like.

Urea-based and bis-urea based compounds and analogues thereof are disclosed. These compounds are useful in the treatment of androgen-dependent diseases or disorders and androgen receptor-mediated diseases or disorders. Specifically, the compounds are useful in the treatment of diseases or disorders that are AR negative.